• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

左心疾病所致肺动脉高压的动物模型。

Animal models of pulmonary hypertension due to left heart disease.

机构信息

Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.

DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Berlin, Germany.

出版信息

Animal Model Exp Med. 2022 Sep;5(3):197-206. doi: 10.1002/ame2.12214. Epub 2022 Feb 9.

DOI:10.1002/ame2.12214
PMID:35234367
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9240728/
Abstract

Pulmonary hypertension due to left heart disease (PH-LHD) is regarded as the most prevalent form of pulmonary hypertension (PH). Indeed, PH is an independent risk factor and predicts adverse prognosis for patients with left heart disease (LHD). Clinically, there are no drugs or treatments that directly address PH-LHD, and treatment of LHD alone will not also ameliorate PH. To target the underlying physiopathological alterations of PH-LHD and to develop novel therapeutic approaches for this population, animal models that simulate the pathophysiology of PH-LHD are required. There are several available models for PH-LHD that have been successfully employed in rodents or large animals by artificially provoking an elevated pressure load on the left heart, which by transduction elicits an escalated pressure in pulmonary artery. In addition, metabolic derangement combined with aortic banding or vascular endothelial growth factor receptor antagonist is also currently applied to reproduce the phenotype of PH-LHD. As of today, none of the animal models exactly recapitulates the condition of patients with PH-LHD. Nevertheless, the selection of an appropriate animal model is essential in basic and translational studies of PH-LHD. Therefore, this review will summarize the characteristics of each PH-LHD animal model and discuss the advantages and limitations of the different models.

摘要

由左心疾病(PH-LHD)引起的肺动脉高压被认为是最常见的肺动脉高压(PH)形式。事实上,PH 是左心疾病(LHD)患者的独立危险因素,并预测不良预后。临床上,没有药物或治疗方法可以直接针对 PH-LHD,单独治疗 LHD 也不会改善 PH。为了针对 PH-LHD 的潜在病理生理改变,并为该人群开发新的治疗方法,需要模拟 PH-LHD 病理生理学的动物模型。有几种可用于 PH-LHD 的模型已经在啮齿动物或大型动物中成功应用,通过人为地对左心施加升高的压力负荷,从而在肺动脉中引起升高的压力。此外,代谢紊乱结合主动脉缩窄或血管内皮生长因子受体拮抗剂也可用于重现 PH-LHD 的表型。截至今天,没有一种动物模型能完全重现 PH-LHD 患者的情况。然而,选择合适的动物模型对于 PH-LHD 的基础和转化研究至关重要。因此,本综述将总结每种 PH-LHD 动物模型的特点,并讨论不同模型的优缺点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec7c/9240728/18bb59b0c6b3/AME2-5-197-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec7c/9240728/164eb032e932/AME2-5-197-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec7c/9240728/18bb59b0c6b3/AME2-5-197-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec7c/9240728/164eb032e932/AME2-5-197-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec7c/9240728/18bb59b0c6b3/AME2-5-197-g003.jpg

相似文献

1
Animal models of pulmonary hypertension due to left heart disease.左心疾病所致肺动脉高压的动物模型。
Animal Model Exp Med. 2022 Sep;5(3):197-206. doi: 10.1002/ame2.12214. Epub 2022 Feb 9.
2
Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure.西地那非可预防舒张性心力衰竭大鼠模型的肺血管内皮功能障碍和肺血管重构。
Circ Heart Fail. 2011 Mar;4(2):198-206. doi: 10.1161/CIRCHEARTFAILURE.110.957050. Epub 2011 Jan 7.
3
Metabolic Syndrome Exacerbates Pulmonary Hypertension due to Left Heart Disease.代谢综合征加重左心疾病所致肺动脉高压。
Circ Res. 2019 Aug 2;125(4):449-466. doi: 10.1161/CIRCRESAHA.118.314555. Epub 2019 Jun 3.
4
A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats.左心疾病所致肺动脉高压逆向血管重构的大鼠模型主动脉去带术
J Vis Exp. 2022 Mar 1(181). doi: 10.3791/63502.
5
Pulmonary veins in the normal lung and pulmonary hypertension due to left heart disease.正常肺的肺静脉和左心疾病引起的肺动脉高压。
Am J Physiol Lung Cell Mol Physiol. 2013 Nov 15;305(10):L725-36. doi: 10.1152/ajplung.00186.2013. Epub 2013 Sep 13.
6
An updated review of experimental rodent models of pulmonary hypertension and left heart disease.肺动脉高压和左心疾病实验性啮齿动物模型的最新综述。
Front Pharmacol. 2024 Jan 8;14:1308095. doi: 10.3389/fphar.2023.1308095. eCollection 2023.
7
Pulmonary hypertension associated with left heart disease.与左心疾病相关的肺动脉高压。
Herz. 2023 Aug;48(4):266-273. doi: 10.1007/s00059-023-05189-z. Epub 2023 Jun 8.
8
Pulmonary hypertension due to left heart disease: The prognostic implications of diastolic pulmonary vascular pressure gradient.左心疾病所致肺动脉高压:舒张期肺血管压力梯度的预后意义
J Cardiol. 2016 Jun;67(6):555-9. doi: 10.1016/j.jjcc.2015.07.015. Epub 2015 Aug 20.
9
Understanding the Pathobiology of Pulmonary Hypertension Due to Left Heart Disease.理解左心疾病所致肺动脉高压的病理生理学。
Circ Res. 2022 Apr 29;130(9):1382-1403. doi: 10.1161/CIRCRESAHA.122.319967. Epub 2022 Apr 28.
10
Pulmonary Hypertension Due to Left Heart Disease: Diagnosis, Pathophysiology, and Therapy.左心疾病所致肺动脉高压:诊断、病理生理学与治疗。
Hypertension. 2020 Jun;75(6):1397-1408. doi: 10.1161/HYPERTENSIONAHA.119.14330. Epub 2020 Apr 27.

引用本文的文献

1
Is Inducible Nitric Oxide Synthase (iNOS) Promising as a New Target Against Pulmonary Hypertension?诱导型一氧化氮合酶(iNOS)作为抗肺动脉高压的新靶点有前景吗?
Antioxidants (Basel). 2025 Mar 21;14(4):377. doi: 10.3390/antiox14040377.
2
Dysregulated fatty acid metabolism in pericardiac adipose tissue of pulmonary hypertension due to left heart disease mice.左心疾病所致肺动脉高压小鼠的心周脂肪组织中脂肪酸代谢失调
FASEB J. 2025 Feb 15;39(3):e70355. doi: 10.1096/fj.202402842R.
3
Early Alteration of Right Ventricle-Pulmonary Artery Coupling in Experimental Heart Failure With Preserved Ejection Fraction.

本文引用的文献

1
Identification of Hypoxia Induced Metabolism Associated Genes in Pulmonary Hypertension.肺动脉高压中缺氧诱导的代谢相关基因的鉴定
Front Pharmacol. 2021 Nov 5;12:753727. doi: 10.3389/fphar.2021.753727. eCollection 2021.
2
Pulmonary Vascular Resistance Estimated by Echocardiography in Dogs With Myxomatous Mitral Valve Disease and Pulmonary Hypertension Probability.通过超声心动图评估患有黏液瘤样二尖瓣疾病和肺动脉高压可能性的犬的肺血管阻力。
Front Vet Sci. 2021 Oct 26;8:771726. doi: 10.3389/fvets.2021.771726. eCollection 2021.
3
Metabolic Syndrome Mediates ROS-miR-193b-NFYA-Dependent Downregulation of Soluble Guanylate Cyclase and Contributes to Exercise-Induced Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction.
实验性射血分数保留心力衰竭中心脏右心室-肺动脉耦联的早期改变。
J Am Heart Assoc. 2024 Jun 4;13(11):e032201. doi: 10.1161/JAHA.123.032201. Epub 2024 May 23.
4
A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function.左心衰竭相关性肺动脉高压治疗探索路线图。欧洲心脏病学会心力衰竭协会(HFA)和欧洲心脏病学会肺循环与右心室功能工作组的科学声明。
Eur J Heart Fail. 2024 Apr;26(4):707-729. doi: 10.1002/ejhf.3236. Epub 2024 Apr 19.
5
A Novel Rat Model of Mild Pulmonary Hypertension Associated with Pulmonary Venous Congestion Induced by Left Pulmonary Vein Banding.一种通过左肺静脉结扎诱导的伴有肺静脉淤血的轻度肺动脉高压新型大鼠模型。
Int J Mol Sci. 2024 Feb 29;25(5):2827. doi: 10.3390/ijms25052827.
6
An updated review of experimental rodent models of pulmonary hypertension and left heart disease.肺动脉高压和左心疾病实验性啮齿动物模型的最新综述。
Front Pharmacol. 2024 Jan 8;14:1308095. doi: 10.3389/fphar.2023.1308095. eCollection 2023.
7
Catheterization of Pulmonary and Carotid Arteries for Concurrent Measurement of Mean Pulmonary and Systemic Arterial Pressure in Rat Models of Pulmonary Arterial Hypertension.在肺动脉高压大鼠模型中经导管插入肺动脉和颈动脉以同步测量平均肺动脉压和体动脉压
Bio Protoc. 2023 Aug 20;13(16):e4737. doi: 10.21769/BioProtoc.4737.
8
Heart diseases, hypertension and effects of antihypertensive medications: Is hypertension a true risk factor of heart diseases?心脏病、高血压和降压药物的作用:高血压是心脏病的真正危险因素吗?
Front Public Health. 2022 Oct 31;10:929840. doi: 10.3389/fpubh.2022.929840. eCollection 2022.
9
Corrigendum.勘误
Animal Model Exp Med. 2022 Oct;5(5):489. doi: 10.1002/ame2.12286. Epub 2022 Oct 22.
代谢综合征通过 ROS-miR-193b-NFYA 依赖性下调可溶性鸟苷酸环化酶介导,并导致射血分数保留的心力衰竭中的运动诱导性肺动脉高压。
Circulation. 2021 Aug 24;144(8):615-637. doi: 10.1161/CIRCULATIONAHA.121.053889. Epub 2021 Jun 23.
4
Mechanical stretching of the pulmonary vein mediates pulmonary hypertension due to left heart disease by regulating SAC/MAPK pathway and the expression of IL-6 and TNF-α.机械拉伸肺静脉通过调节 SAC/MAPK 通路和白细胞介素 6(IL-6)和肿瘤坏死因子-α(TNF-α)的表达介导左心疾病相关肺动脉高压。
J Cardiothorac Surg. 2021 May 10;16(1):127. doi: 10.1186/s13019-021-01471-5.
5
Combined pre- and post-capillary pulmonary hypertension: The clinical implications for patients with heart failure.合并毛细血管前和毛细血管后肺动脉高压:心力衰竭患者的临床意义。
PLoS One. 2021 Mar 2;16(3):e0247987. doi: 10.1371/journal.pone.0247987. eCollection 2021.
6
Efficacy of Beraprost Sodium Combined with Sildenafil and Its Effects on Vascular Endothelial Function and Inflammation in Patients Experiencing Left Heart Failure Complicated with Pulmonary Arterial Hypertension.贝前列素钠联合西地那非治疗左心衰竭合并肺动脉高压患者的疗效及其对血管内皮功能和炎症的影响
Med Sci Monit. 2021 Feb 3;27:e928413. doi: 10.12659/MSM.928413.
7
Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload.Kcnk3 功能障碍可加重左心室压力超负荷所致肺动脉高压的发展。
Cardiovasc Res. 2021 Nov 1;117(12):2474-2488. doi: 10.1093/cvr/cvab016.
8
Impact of targeted pulmonary arterial hypertension therapy in patients with combined post- and precapillary pulmonary hypertension.靶向肺动脉高压治疗对合并前、后毛细血管性肺动脉高压患者的影响。
Am Heart J. 2021 May;235:74-81. doi: 10.1016/j.ahj.2021.01.003. Epub 2021 Jan 8.
9
DNA methyltransferase 3B deficiency unveils a new pathological mechanism of pulmonary hypertension.DNA 甲基转移酶 3B 缺乏揭示了肺动脉高压的一种新病理机制。
Sci Adv. 2020 Dec 9;6(50). doi: 10.1126/sciadv.aba2470. Print 2020 Dec.
10
The beneficial effects of angiotensin-converting enzyme II (ACE2) activator in pulmonary hypertension secondary to left ventricular dysfunction.血管紧张素转化酶 2(ACE2)激活剂对左心功能障碍性肺动脉高压的有益作用。
Int J Med Sci. 2020 Sep 16;17(16):2594-2602. doi: 10.7150/ijms.48096. eCollection 2020.